Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Accelerate Diabetic Wound Healing via Ameliorating Oxidative Stress and Promoting Angiogenesis.

Yan Xv,Yiqiang Hu,Yori Endo,Faqi Cao,Wu Zhou,Peng Zhang,Lang Chen,Chenchen Yan,Hang Xue,Ze Lin,Guohui Liu,Liangcong Hu

doi:10.3389/fbioe.2022.829868

Abstract

Diabetic wounds remain a great challenge for clinicians due to the multiple bacterial infections and oxidative damage. Exosomes, as an appealing nanodrug delivery system, have been widely applied in the treatment of diabetic wounds. Endovascular cells are important component cells of the vascular wall. Herein, we investigated the effects of HUCMSCs and HUC-Exos (exosomes secreted by HUCMSCs) on diabetic wound healing. In this study, HUVECs were coincubated with HUCMSCs, and HUC-Exos were utilized for in vitro and in vivo experiments to verify their roles in the regulation of diabetic wound healing. Our results demonstrated that HUCMSCs have the ability to regulate oxidative stress injuries of endothelial cells through exosomes and accelerate diabetic cutaneous wound healing in vitro. The present study suggests that HUC-Exos accelerate diabetic cutaneous wound healing, providing a promising therapeutic strategy for chronic diabetic wound repair.

Highlights

With the diet changes and rising average age of the global population, the prevalence of diabetes is on the rise (Martinengo et al, 2019; Kowluru, 2020)
To evaluate the oxidative stress damage caused by the hyperglycemic environment, we set up three groups of HUVECs in a culture medium with different glucose concentrations
Results show that the cells treated with high-level glucose concentrations had higher fluorescence intensity compared with the low-level group and middle-level group

Summary

Introduction

With the diet changes and rising average age of the global population, the prevalence of diabetes is on the rise (Martinengo et al, 2019; Kowluru, 2020). The main comorbidities of diabetes include chronic recalcitrant cutaneous wounds due to multiple drug-resistant bacterial infections, angiopathy, and oxidative damage to the microenvironment (Castleberry et al, 2016; Armstrong et al, 2017). 15%–25% are at risk for diabetic foot (Reardon et al, 2020). The recurrence rate of diabetic foot cannot be ignored. 40% of diabetic foot patients have onset symptoms after 1 year, and the probability of recurrence symptoms within 5 years is 65% (Lim et al, 2017).

Objectives

Results

Conclusion